The pharmacokinetics, metabolism, and excretion of aromatically labeled tritiated vincristine (VCR) was examined in 4 patients. Clearance of radioactivity from the blood was triphasic with half-life t1/2 values of 0.85, 7.4, and 164 min. The initial phases probably represent distribution and binding to formed blood elements which exceeded 50% of the administered dose by 20 min. Excretion of radioactivity was principally fecal, with 33% recovered in the feces by 24 hr and 69% by 72 hr. Considerably less radioactivity (12%) was excreted in the urine over the 72-hr period. Approximately 40% of fecally excreted and 46% of urinary excreted radiolabel represented metabolites, which suggests that at least 34% of the VCR dose was excreted as metabolies. Plasma metabolites represented from less than 1% to 30% or more of radioactivity in plasma. Ultraviolet spectral analysis of all metabolites revealed preservation of the intact VCR dimer, which suggests that metabolism involves alteration of side groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cpt1977224430 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetics, efficacy, and safety of subcutaneous versus intravenous rituximab in previously untreated Chinese patients with CD20+ diffuse large B-cell lymphoma: a phase II randomized controlled trial.
Leuk Lymphoma
January 2025
Department of Internal Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Subcutaneous (SC) rituximab has demonstrated advantages over intravenous (IV) administration; however, insufficient data exist on its use with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Chinese patients with diffuse large B-cell lymphoma (DLBCL). This multicenter, phase II, randomized, controlled study was conducted across China between February 2021 and October 2022. Fifty adult patients with previously untreated CD20-positive DLBCL were randomized to receive one cycle of IV rituximab and seven cycles of SC rituximab (R-CHOP; = 26), or eight cycles of IV rituximab (R-CHOP; = 24), combined with six or eight cycles of CHOP.
View Article and Find Full Text PDFVincristine loaded pegylated liposomal drug delivery for efficient treatment of acute lymphoblastic leukaemia.
Pak J Pharm Sci
September 2024
Hematology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, China.
Vincristine sulfate (VIN) is commonly employed as a cytotoxic agent in the treatment of hematological malignancies, particularly acute lymphoblastic leukaemia (ALL). However, its maximum therapeutic benefits have been hindered due to the dose-dependent neurotoxic effects it can induce, which traditionally manifest as autonomic and peripheral sensory-motor neuropathy. The innovative approach aimed to address VIN's neurotoxic limitations while preserving its therapeutic efficacy in combating hematological malignancies, including ALL.
View Article and Find Full Text PDFPolymeric nanoparticles loaded with vincristine and carbon dots for hepatocellular carcinoma therapy and imaging.
Sci Rep
October 2024
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria.
Chemotherapy for hepatoblastoma is limited by organ toxicity and poor outcomes, prompting the search for new, more effective treatments with minimal side effects. Vincristine sulfate, a potent chemotherapeutic, faces challenges due to P-glycoprotein-mediated resistance and its systemic toxicity. Nanoparticles offer a promising solution by improving pharmacokinetics, targeting tumor cells, thus reducing side effects.
View Article and Find Full Text PDFPharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine-Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients.
Clin Pharmacol Ther
October 2024
Infection, Immunity, Inflammation Section, UCL Institute of Child Health, London, UK.
Article Synopsis
- Vincristine can lead to vincristine-induced peripheral neuropathy (VIPN) in children with acute lymphoblastic leukemia (ALL), and this study aimed to understand the factors that affect its pharmacokinetics and pharmacodynamics.
- A total of 79 pediatric patients were analyzed, revealing that certain genetic factors and interactions with other drugs, like posaconazole, significantly influence the metabolism of vincristine and its association with VIPN risk.
- The research suggests that monitoring vincristine levels during treatment is vital for adjusting dosages and personalizing therapy to mitigate the risk of VIPN.
Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy.
Int J Mol Sci
August 2024
Pharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, Avda. de las Fuerzas Armadas 2, 18004 Granada, Spain.
Cancer is the leading cause of disease-related death among children. Vincristine (VCR), a key component of childhood cancer treatment protocols, is associated with the risk of peripheral neuropathy (PN), a condition that may be reversible upon drug discontinuation but can also leave lasting sequelae. Single nucleotide polymorphism (SNP) in genes involved in VCR pharmacokinetics and pharmacodynamics have been investigated in relation to an increased risk of PN.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!